StockNews.AI
MBX
StockNews.AI
6 hrs

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

1. MBX announces topline results for Phase 2 trial of canvuparatide. 2. Results to be discussed in an investor webcast on September 22. 3. Canvuparatide targets chronic hypoparathyroidism, a significant market need. 4. MBX focuses on novel precision peptide therapies for endocrine disorders. 5. Upcoming results could impact MBX’s stock based on trial outcomes.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive trial results can lead to increased investor confidence and stock price.

How important is it?

The trial results could confirm the efficacy of a key product, directly influencing MBX’s market potential.

Why Short Term?

Immediate impact expected from upcoming results; similar situations have led to rapid price movements.

Related Companies

ISEEPRTAENPH
September 19, 2025 16:18 ET  | Source: MBX Biosciences, Inc. CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) and host an investor webcast on Monday, September 22. The Company will host a conference call and webcast at 8 am ET on Monday, September 22 to discuss the results from the Avail™ Phase 2 trial. Those who would like to participate may access the live webcast here or dial 1-877-407-0779 (US) or 1-201-389-0914 (international). The live and archived webcast of the call and slide presentation will be available in the Investors section of the Company’s website at https://investors.mbxbio.com/news-events/events. About MBX Biosciences MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn. Media Contact:Katie Beach OltsikInizio Evoke CommsIECommsMBX@inizioevoke.com (937) 232-4889 Investor Contact:Jim DeNikeMBX Biosciencesjdenike@mbxbio.com

Related News